363 related articles for article (PubMed ID: 30907072)
1. Hope and challenge: Precision medicine in bladder cancer.
Su H; Jiang H; Tao T; Kang X; Zhang X; Kang D; Li S; Li C; Wang H; Yang Z; Zhang J; Li C
Cancer Med; 2019 Apr; 8(4):1806-1816. PubMed ID: 30907072
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for precision medicine in bladder cancer.
Kojima T; Kawai K; Miyazaki J; Nishiyama H
Int J Clin Oncol; 2017 Apr; 22(2):207-213. PubMed ID: 27896485
[TBL] [Abstract][Full Text] [Related]
3. Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
Song BN; Kim SK; Mun JY; Choi YD; Leem SH; Chu IS
EBioMedicine; 2019 Dec; 50():238-245. PubMed ID: 31735557
[TBL] [Abstract][Full Text] [Related]
4. Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer.
Jin F; Shahid M; Kim J
Adv Exp Med Biol; 2021; 1306():61-80. PubMed ID: 33959906
[TBL] [Abstract][Full Text] [Related]
5. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
[TBL] [Abstract][Full Text] [Related]
7. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
8. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Diagnosis, Molecular Taxonomy, and Treatment of Bladder Cancer.
Ulamec M; Murgić J; Novosel L; Tomić M; Terlević R; Tomašković I; Jazvić M; Froebe A; Krušlin B
Acta Med Acad; 2021 Apr; 50(1):143-156. PubMed ID: 34075770
[TBL] [Abstract][Full Text] [Related]
10. Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology.
Dyrskjøt L; Ingersoll MA
Curr Opin Urol; 2018 Nov; 28(6):598-603. PubMed ID: 30138123
[TBL] [Abstract][Full Text] [Related]
11. Economic aspects of bladder cancer: what are the benefits and costs?
Sievert KD; Amend B; Nagele U; Schilling D; Bedke J; Horstmann M; Hennenlotter J; Kruck S; Stenzl A
World J Urol; 2009 Jun; 27(3):295-300. PubMed ID: 19271220
[TBL] [Abstract][Full Text] [Related]
12. microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
Amir S; Mabjeesh NJ
Histol Histopathol; 2017 Feb; 32(2):107-119. PubMed ID: 27586262
[TBL] [Abstract][Full Text] [Related]
13. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
14. Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions.
Zhang X; Yang H; Zhang R
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31387972
[TBL] [Abstract][Full Text] [Related]
15. [French ccAFU guidelines – Update 2018–2020: Bladder cancer].
Rouprêt M; Neuzillet Y; Pignot G; Compérat E; Audenet F; Houédé N; Larré S; Masson-Lecomte A; Colin P; Brunelle S; Xylinas E; Roumiguié M; Méjean A
Prog Urol; 2019 Sep; 28(S1):R48-R80. PubMed ID: 32093463
[TBL] [Abstract][Full Text] [Related]
16. Follow-up procedures for non-muscle-invasive bladder cancer: an update.
Anastasiadis A; Cordeiro E; Bus MT; Alivizatos G; de la Rosette JJ; de Reijke TM
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1229-41. PubMed ID: 23098122
[TBL] [Abstract][Full Text] [Related]
17. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer.
Ilijazi D; Abufaraj M; Hassler MR; Ertl IE; D'Andrea D; Shariat SF
Expert Rev Mol Diagn; 2018 Apr; 18(4):347-356. PubMed ID: 29542328
[TBL] [Abstract][Full Text] [Related]
18. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
19. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
20. Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer.
Zhao J; Li J; Zhang R
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188926. PubMed ID: 37230421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
